Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 1/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.52 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.52 |
| ▸ | CMA1 | P23946 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.30 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974484 | 1.00 | PRKAG1 (0.52) | PRKAG1PRKAA1PRKAB1CMA1SMN1; SMN2 | |
| SCHEMBL1977138 | 1.00 | PRKAG1 (0.52) | PRKAG1PRKAA1PRKAB1CMA1SMN1; SMN2 | |
| SCHEMBL1977870 | 1.00 | PRKAG1 (0.52) | PRKAG1PRKAA1PRKAB1CMA1SMN1; SMN2 | |
| SCHEMBL1973119 | 1.00 | PRKAG1 (0.52) | PRKAG1PRKAA1PRKAB1CMA1SMN1; SMN2 | |
| SCHEMBL1974577 | 0.92 | PRKAG1 (0.44) | PRKAG1PRKAA1PRKAB1SMN1; SMN2IDH1 | |
| SCHEMBL12555105 | 0.92 | PRKAG1 (0.44) | PRKAG1PRKAA1PRKAB1SMN1; SMN2IDH1 | |
| SCHEMBL1974056 | 0.90 | PRKAG1 (0.63) | PRKAG1PRKAA1PRKAB1CMA1SMN1; SMN2 | |
| SCHEMBL1973985 | 0.90 | PRKAG1 (0.63) | PRKAG1PRKAA1PRKAB1CMA1SMN1; SMN2 | |
| SCHEMBL16477284 | 0.90 | PRKAG1 (0.63) | PRKAG1PRKAA1PRKAB1CMA1SMN1; SMN2 | |
| SCHEMBL1973983 | 0.90 | PRKAG1 (0.63) | PRKAG1PRKAA1PRKAB1CMA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354443-B2 | Cyclopropane indolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | claimed |
| EP-2509946-B1 | SPIRO INDOLE-CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8354443-B2 | Cyclopropane indolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354443-B2 | Cyclopropane indolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354443-B2 | Cyclopropane indolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| WO-2011070039-A1 | SPIRO INDOLE - CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | GPR119, CPT1A, IRS1 | PRKAG1 2038/4885PRKAA1 1509/4885PRKAB1 1537/4885 |
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | GPR119, CPT1A, IRS1 | PRKAG1 2091/4885PRKAA1 1553/4885PRKAB1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.